| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.3 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |